Wedbush downgraded Mersana Therapeutics (MRSN) to Neutral from Outperform after Day One Biopharmaceuticals (DAWN) agreed to acquire Mersana for total consideration of up to $55.25 per share in cash.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRSN:
- Why Is Mersana Therapeutics Stock (MRSN) Up Today?
- Mersana Therapeutics Announces Merger with Day One
- Day One Biopharmaceuticals to acquire Mersana Therapeutics for up to $285M
- MRSN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Buy Rating for Mersana Therapeutics: Promising Potential in Post-Topo TNBC with Emi-Le ADC